| 2/27/2023 | BKCVDDEMIGPV | Market Commentary: Triumph, Teva on deck; Tegna tanks on FCC acquisition opposition; TransDigm, Uniti improve
|
| 7/27/2022 | BKCVDDEMIGPV | Market Commentary: Avient prices; secondary surges post-Fed; cross-over credits in demand; Teva gains on settlement
|
| 11/4/2021 | BKCVDDEMIGPV | Market Commentary: DCP Midstream, Asbury Automotive price; Teva active; Continental gains; CommScope sinks
|
| 11/3/2021 | BKCVDDEMIGPV | Market Commentary: Junk secondary unmoved by Fed tapering statement; Teva flat; Jane Street on a 101-handle
|
| 11/1/2021 | BKCVDDEMIGPV | Market Commentary: Mr. Cooper, Navient price; loanDepot gains on earnings beat; PG&E active
|
| 11/18/2019 | BKCVDDEMIGPV | Market Commentary: iHeart, Boyd, Mattel, MSCI add-on price; Prestige Brands trades up
|
| 11/8/2019 | BKCVDDEMIGPV | Market Commentary: Wesco PattonAir downsizes; Albertsons improves; LPL up; Teva active; Wildhorse rebounds
|
| 11/8/2019 | BKCVDDEMIGPV | Market Commentary: Wesco PattonAir downsizes; Albertsons improves; LPL up; Teva active; Wildhorse rebounds
|
| 10/21/2019 | BKCVDDEMIGPV | Market Commentary: United Rentals, KB Home price; newer notes trade; Teva lifted; Coty falls; WeWork higher
|
| 10/18/2019 | BKCVDDEMIGPV | Market Commentary: Neptune Energy adds; Evoca prices; Thursday issuance higher; Teva up; WeWork better
|
| 10/16/2019 | BKCVDDEMIGPV | Market Commentary: Merlin, Speedway price; new Charter notes rise; pharma names up; Sprint, T-Mobile higher
|
| 8/28/2019 | BKCVDDEMIGPV | Market Commentary: Pharma space under pressure; Rackspace higher; Tallgrass negative; oil names rise
|
| 8/27/2019 | BKCVDDEMIGPV | Market Commentary: Pharma names see negativity; Range Resources varies; GTT declines
|
| 8/13/2019 | BKCVDDEMIGPV | Market Commentary: Post Labor Day pipeline eyed; Tenet bounces off lows; Teva drops; Goodyear Tire rises
|
| 7/23/2019 | BKCVDDEMIGPV | Market Commentary: JBS USA, Five Point add-on price; Teva in focus; LSC Communications craters
|
| 7/5/2019 | BKCVDDEMIGPV | Market Commentary: Trading light; Altice USA backs off gains; Teva active but flat; funds add $800 million
|
| 6/3/2019 | BKCVDDEMIGPV | Market Commentary: Multi-Color, Grubhub on tap; Neiman Marcus, GCI price; Teva in focus, gains; Altice up
|
| 5/29/2019 | BKCVDDEMIGPV | Market Commentary: CNO Financial prices; Frontier gains; Teva’s downward spiral continues; CRC drops
|
| 5/28/2019 | BKCVDDEMIGPV | Market Commentary: CNO Financial, GoDaddy on tap; Fiat up on merger; Teva drops post settlement
|
| 5/15/2019 | BKCVDDEMIGPV | Market Commentary: Transocean prices; Berry on tap; VistaJet active; Teva, Commscope under pressure
|
| 5/13/2019 | BKCVDDEMIGPV | Market Commentary: Eldorado on tap; Bausch Health weakens; Charter below par; Weatherford, Teva down
|
| 1/4/2019 | BKCVDDEMIGPV | Market Commentary: Risk-on sentiment returns; CDX sees largest single-day gain in four years; energy outperforms
|
| 1/3/2019 | BKCVDDEMIGPV | Market Commentary: No new deals in sight; trading volume light; Western Digital active; Qorvo drops; Teva up
|
| 10/11/2018 | BKCVDDEMIGPV | Market Commentary: Millicom prices; TransDigm rises on acquisition; energy mixed; Teva Pharaceutical improves
|
| 7/27/2018 | BKCVDDEMIGPV | Market Commentary: Hi-Crush prices, euro primary active; Party City’s new issue lower; Teva slides
|
| 7/26/2018 | BKCVDDEMIGPV | Market Commentary: Party City prices; Teva improves; Aleris acquired; SuperValu bought; funds off $548 million
|
| 7/20/2018 | BKCVDDEMIGPV | Market Commentary: Comstock prices; Bruin carried over; secondary trading light; IHS Markit eyed; Teva active
|
| 3/16/2018 | BKCVDDEMIGPV | Market Commentary: Tullow, Husky lead busy primary; Mattel trades on Toys shutdown; Teva still trades under par
|
| 3/7/2018 | BKCVDDEMIGPV | Market Commentary: Upsized Teva megadeal prices; new Ball notes busiest; CIT trades up; Frontier mostly up
|
| 3/6/2018 | BKCVDDEMIGPV | Market Commentary: Three-part CIT drive-by leads deal parade; Ball, William Lyons, Buena Vista also price
|
| 12/14/2017 | BKBWCVHYIG | Teva to use all available cash flow to cut debt until end of 2020
|
| 12/14/2017 | BKCVEMIG | Moody’s reviews Teva Pharmaceutical
|
| 11/6/2017 | BKCVEMIG | Fitch downgrades Teva to BB
|
| 11/3/2017 | BKCVEMIG | S&P revises Teva to negative
|
| 9/20/2017 | BKCVEMIG | S&P downgrades Teva
|
| 8/4/2017 | BKCVIG | Fitch downgrades Teva to BBB-
|
| 8/4/2017 | BKCVEMIG | Moody's downgrades Teva
|
| 2/3/2017 | BKCVEMIG | S&P: Teva Pharmaceutical outlook to negative
|
| 8/2/2016 | BKCVEMIG | Moody’s downgrades Teva to Baa2
|
| 7/22/2016 | BKCVEMIG | Fitch rates Teva bonds BBB
|
| 7/20/2016 | IG | Market Commentary: Primary action thins; Citigroup subordinated notes mixed; Teva stronger; credit spreads firm
|
| 7/20/2016 | BKCVEMIG | Fitch downgrades Teva, rates bond BBB
|
| 7/20/2016 | IG | Market Commentary: Morning Commentary: Teva notes tighten; Citigroup paper unchanged; Libor yield hits 70 bps
|
| 7/19/2016 | EMIG | New Issue: Israel’s Teva Pharmaceutical details pricing of $15 billion of notes in six tranches
|
| 7/18/2016 | IG | Market Commentary: Teva prices $15 billion; Citi, Wells Fargo tap market; bonds mixed; credit spreads improve
|
| 7/18/2016 | EMIG | New Issue: Israel’s Teva Pharmaceutical details pricing of $15 billion of notes in six tranches
|
| 7/18/2016 | BKCVEMIG | S&P rates Teva notes BBB
|
| 7/18/2016 | BKCVEMIG | Moody’s rates Teva notes Baa2
|
| 7/18/2016 | IG | Market Commentary: Morning Commentary: Teva offering in deal pipeline; JPMorgan eases; credit spreads unchanged
|
| 7/18/2016 | EMIG | Teva Pharmaceuticals in the market with fixed-, floating-rate notes
|
| 7/13/2016 | IG | Market Commentary: Japan Bank, Bank of Montreal, International Finance in primary; Anheuser-Busch flat on day
|
| 7/13/2016 | EMIG | Teva sets investor call dates ahead of more than $20 billion equivalent of debt offerings
|
| 7/13/2016 | BKBWEMIG | Teva planned net debt funding for Allergan purchase down by $4 billion
|
| 7/13/2016 | BKCVEMIG | S&P downgrades Teva
|
| 7/13/2016 | EMIG | Teva expected to tap markets for more than $20 billion of debt to fund acquisition
|
| 11/25/2015 | BKCVEMIG | S&P rates Teva loan BBB+
|
| 8/3/2015 | BKEMIG | Israel’s Teva details commitments for $33.75 billion in facilities
|
| 7/31/2015 | BKEMIG | Israel’s Teva gets financing commitments for up to $33.75 billion
|
| 7/28/2015 | BKCVEMIG | S&P lowers Teva Pharmaceutical
|
| 7/27/2015 | BKBWEMIGLM | Teva Pharmaceuticals to obtain up to $27 billion of debt to buy Allergan’s generics business
|
| 7/27/2015 | BKCVEMIG | Moody’s cuts Teva Pharmaceutical to Baa1
|
| 4/22/2015 | BKCVEMIG | Fitch: Teva on watch after merger news
|
| 4/22/2015 | BKCVEMIG | S&P: Teva on watch after Mylan deal announced
|
| 4/21/2015 | BKCVEMIG | Moody's changes Teva outlook to negative
|
| 3/31/2015 | BKCVEMIG | Moody's: Teva unchanged
|
| 3/24/2015 | HYIG | Market Commentary: New deal from Teva Pharmaceuticals; risk aversion grows; Asia mixed, Lat-Am weakens
|
| 3/24/2015 | BKCVEMIG | Moody's rates Teva notes A3
|
| 3/24/2015 | BKCVEMIG | S&P rates Teva notes A-
|
| 3/24/2015 | BKCVEMIG | Fitch assigns BBB+ to Teva bond
|
| 2/27/2015 | EMIGLM | Israel’s Teva ups tender purchase amount to $1.3 billion; pricing set
|
| 2/19/2015 | BKCVEMIG | Moody’s revises Teva to stable
|
| 2/12/2015 | EMIGLM | Teva Pharmaceutical tenders for up to $1 billion of four note series
|
| 3/1/2013 | EMIGLM | Israel's Teva Pharmaceutical calls $500 million 5.55% notes due 2016
|
| 12/18/2012 | IGLM | Teva Pharmaceutical Finance to redeem $1 billion senior notes due 2014
|
| 12/17/2012 | IG | Market Commentary: Midday Commentary: Primary issuance slows; Teva Pharmaceutical notes trading weaker
|
| 12/17/2012 | IG | Market Commentary: Precision Castparts, Florida Power sell as pipeline slows; Citi weakens; Teva bonds active
|
| 12/14/2012 | IG | Market Commentary: Market Commentary: Strong tone caps off week's trading; Teva notes tighten in secondary
|
| 12/14/2012 | IG | Market Commentary: Up to $10 billion of new bonds seen in coming week before year-end wind-down; Teva notes firm
|
| 12/13/2012 | IGLM | Teva Pharmaceutical to redeem $1 billion 1.7% notes via new offerings
|
| 12/13/2012 | IG | Israel's Teva Pharmaceutical units selling benchmark senior notes due 2020, 2022 on Thursday
|
| 12/13/2012 | IG | New Issue: Teva units price $2 billion of senior notes due 2020, 2022
|
| 12/13/2012 | IG | Market Commentary: Teva sells two maturities, joined by HSBC, Williams, NewMarket; secondary tone weaker
|
| 4/3/2012 | CVEMIG | S&P rates Teva notes A-
|
| 4/2/2012 | CVEMIG | Moody's rates Teva notes A3
|
| 3/29/2012 | CVEMIG | S&P rates Teva notes A-
|
| 12/21/2011 | CVEMIG | Teva to end 2011 with $14.5 billion of debt, expects decrease in 2012
|
| 12/21/2011 | CVEMIG | Moody's: Teva unchanged
|
| 12/9/2011 | CVEMIG | Teva files automatic shelf registration for ADS, debt, units, warrants
|
| 12/6/2011 | BKCVEMIG | Teva has 'robust' rating, 'significant' cash flow for deleveraging
|
| 11/8/2011 | IG | Market Commentary: International Paper brings $1.5 billion; Halliburton sells $1 billion; HP firms; Hershey flat
|
| 11/8/2011 | EMIG | New Issue: Teva Pharmaceutical sells $5 billion of senior notes in six tranches
|
| 11/7/2011 | CVEMIG | S&P assigns Teva notes A-
|
| 11/7/2011 | EMIG | Israel's Teva Pharmaceutical to sell $4 billion of senior notes
|
| 11/7/2011 | IG | Market Commentary: Canadian Railway, Zimmer bring deals; Jefferies bucks sector weakness; telecom bonds widen
|
| 8/2/2011 | CVEMIG | Moody's: Teva unchanged
|
| 5/2/2011 | CVEMIG | Moody's affirms Teva
|
| 5/2/2011 | CVEMIG | Teva plans to use cash, bonds to acquire Cephalon for $6.8 billion
|
| 5/2/2011 | CVEMIG | S&P affirms Teva
|
| 3/16/2011 | CVEMIG | Moody's rates Teva notes A3
|
| 3/16/2011 | EMIG | New Issue: Teva Pharmaceuticals prices $750 million of senior notes in two tranches
|
| 3/16/2011 | IG | Market Commentary: Cliffs Natural sells $1 billion, Teva and AGL Capital price deals; Bank of America widens
|
| 3/16/2011 | CVEMIG | S&P rates Teva notes A-
|
| 6/15/2010 | IG | Market Commentary: Teva, Lincoln National, Pall price deals; BP keeps widening; new deals strong in trading
|
| 6/15/2010 | EMIG | New Issue: Teva Pharmaceutical prices $2.5 billion of senior notes in three tranches
|
| 3/19/2010 | CVEMIG | S&P ups Teva Pharmaceutical
|
| 3/18/2010 | CVEMIG | Moody's affirms Teva Pharmaceuticals
|
| 1/13/2010 | CVEMIG | Moody's lifts Teva
|
| 10/14/2009 | CVEMIG | Moody's upgrades Teva
|
| 6/25/2009 | IG | Market Commentary: Citigroup, Jefferies, Analog Devices, MassMutual, Torchmark sell notes; Merck busy, up again
|
| 1/6/2009 | CVEMIG | Moody's affirms Teva, ups Barr loan
|
| 12/4/2008 | CVEMIG | Teva files automatic shelf registration
|
| 7/18/2008 | BKCVEMIG | Moody's may upgrade Barr, affirms Teva
|
| 7/18/2008 | EMIG | Teva acquires Barr, plans tapping of long-term debt market
|
| 7/18/2008 | IG | Market Commentary: Week of nearly $4 billion ends on quiet note; Freddie Mac announces future issue
|
